Kahraman Öncel
Research Subjects
Kahraman Öncel has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Murat Söker
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Türkiye
2 shared publications - Veysiye Hülya Üzel
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Türkiye
2 shared publications - Kamil Yilmaz
Koc University
1 shared publication - Kamil Yılmaz
Department of Pediatrics Dicle University Medical Faculty Diyarbakır Türkiye
1 shared publication - Murat Solmaz
Department of Pediatrics, Batman Iluh State Hospital, Batman, Türkiye
1 shared publication - Sevda Soker
Dicle University
1 shared publication
Latest Publications
- Open Access
- 26 December 2025
- Published by Zeus Publishing in Journal of Medical and Dental Investigations
- Vol. 6
Retrospective analysis of demographic and clinical characteristics and treatment outcomes of pediatric acute lymphoblastic leukemia patients
Aim: This study aimed to compare treatment outcomes (mortality and relapse) between two pediatric acute lymphoblastic leukemia (ALL) protocols (TR-ALL BFM 2000 vs ALL-IC-BFM 2009) and to describe the demographic, clinical, and laboratory characteristics of patients treated at a single center (2010–2015). Methods: We retrospectively reviewed the medical records of 121 children (<18 years) diagnosed with ALL and treated with either TR-ALL BFM 2000 or ALL-IC-BFM 2009. Baseline characteristics, risk group, immunophenotype, protocol, relapse status, and survival status were recorded. Categorical variables were compared using the chi-square test or Fisher’s exact test, as appropriate (p < 0.05). Results: The cohort was 53.7% male, with a mean age at diagnosis of 7.55 ± 3.89 years. B-cell ALL accounted for 78.5% and T-cell ALL for 21.5%. The overall mortality rate was 11.6% (14/121), and relapse occurred in 5.8% (7/121) of patients. Mortality differed by risk group (SRG 6.5%, IRG 7.3%, HRG 23.5%; p = 0.036). Relapse was higher in T-cell ALL than in B-cell ALL (23.1% vs 1.1%; p = 0.001). Compared with ALL-IC-BFM 2009, TR-ALL BFM 2000 was associated with higher mortality (19.2% vs 5.8%; p = 0.022) and relapse (11.5% vs 1.4%; p = 0.019). Conclusion: In this single-center retrospective cohort study, the high-risk group was associated with higher mortality, and the T-cell immunophenotype was associated with higher relapse. Patients treated with ALL-IC-BFM 2009 had lower crude mortality and relapse rates than those treated with TR-ALL BFM 2000; however, these protocol comparisons should be interpreted cautiously, given potential confounding and limited event numbers.
- 26 December 2025
- Published by Zeus Publishing in Journal of Medical and Dental Investigations
- Vol. 6
Open AccessRetrospective analysis of demographic and clinical characteristics and treatment outcomes of pediatric acute lymphoblastic leukemia patients
Aim: This study aimed to compare treatment outcomes (mortality and relapse) between two pediatric acute lymphoblastic leukemia (ALL) protocols (TR-ALL BFM 2000 vs ALL-IC-BFM 2009) and to describe the demographic, clinical, and laboratory characteristics of patients treated at a single center (2010–2015). Methods: We retrospectively reviewed the medical records of 121 children (<18 years) diagnosed with ALL and treated with either TR-ALL BFM 2000 or ALL-IC-BFM 2009. Baseline characteristics, risk group, immunophenotype, protocol, relapse status, and survival status were recorded. Categorical variables were compared using the chi-square test or Fisher’s exact test, as appropriate (p < 0.05). Results: The cohort was 53.7% male, with a mean age at diagnosis of 7.55 ± 3.89 years. B-cell ALL accounted for 78.5% and T-cell ALL for 21.5%. The overall mortality rate was 11.6% (14/121), and relapse occurred in 5.8% (7/121) of patients. Mortality differed by risk group (SRG 6.5%, IRG 7.3%, HRG 23.5%; p = 0.036). Relapse was higher in T-cell ALL than in B-cell ALL (23.1% vs 1.1%; p = 0.001). Compared with ALL-IC-BFM 2009, TR-ALL BFM 2000 was associated with higher mortality (19.2% vs 5.8%; p = 0.022) and relapse (11.5% vs 1.4%; p = 0.019). Conclusion: In this single-center retrospective cohort study, the high-risk group was associated with higher mortality, and the T-cell immunophenotype was associated with higher relapse. Patients treated with ALL-IC-BFM 2009 had lower crude mortality and relapse rates than those treated with TR-ALL BFM 2000; however, these protocol comparisons should be interpreted cautiously, given potential confounding and limited event numbers.
- Open Access
- 25 August 2021
- Published by Galenos Yayinevi in Güncel Pediatri
- Vol. 19 (2) , 162-167
Evaluation of 36 Patients with Rare Factor Deficiency
- 25 August 2021
- Published by Galenos Yayinevi in Güncel Pediatri
- Vol. 19 (2) , 162-167
Open AccessEvaluation of 36 Patients with Rare Factor Deficiency